Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival

Lee, Dong Hoon; Lee, Jeong Min; Kim, Pyo Nyun; Jang, Yeon Jin; Kang, Tae Wook; Rhim, Hyunchul; Seo, Jiwon; Lee, Young Joon

doi:10.1007/s00330-018-5993-y

Cited by 9 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A string of image-guided percutaneous ablations encompasses a great variety of techniques, including radiofrequency ablation (RFA), microwave ablation (MWA), ethanol injection, and cryoablation [62][63][64][65]. As RFA is the most frequently used ablation modality for HCC [66,67], the main topic addressed in this section is RFA. Although RFA has shown good feasibility in local tumor control for HCC, complete ablation is slightly idealistic, and the relapse rate ranges from 49 to 63% [68].…”

Section: Local Ablationmentioning

confidence: 99%

Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?

et al. 2021

View full text Add to dashboard Cite

With the development of machine learning (ML) algorithms, a growing number of predictive models have been established for predicting the therapeutic outcome of patients with hepatocellular carcinoma (HCC) after various treatment modalities. By using the different combinations of clinical and radiological variables, ML algorithms can simulate human learning to detect hidden patterns within the data and play a critical role in artificial intelligence techniques. Compared to traditional statistical methods, ML methods have greater predictive effects. ML algorithms are widely applied in nearly all steps of model establishment, such as imaging feature extraction, predictive factor classification, and model development. Therefore, this review presents the literature pertaining to ML algorithms and aims to summarize the strengths and limitations of ML, as well as its potential value in prognostic prediction, after various treatment modalities for HCC.

show abstract

Section: Local Ablationmentioning

confidence: 99%

Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, most patients are diagnosed with an advanced stage of disease, and only 20-30% of patients can receive curative treatments (Arizumi et al, 2015;Eilard et al, 2019;Peng et al, 2019;Luedemann et al, 2020). Transarterial chemoembolization (TACE) is the standard therapy for intermediate-stage HCC, which is accepted by several guidelines (Piscaglia and Ogasawara, 2018;Lee et al, 2019). However, it has been reported that not all HCC patients respond to TACE because the patients selected for TACE correspond to a highly heterogeneous population, covering a wide range of tumor burdens, liver function and treatment histories (Maesaka et al, 2020;Xue et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

Wang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Objectives: To develop and validate a predictive model for early refractoriness of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).Methods: In this multicenter retrospective study, a total of 204 consecutive patients who initially underwent TACE were included. Early TACE refractoriness was defined as patients presented with TACE refractoriness after initial two consecutive TACE procedures. Of all patients, 147 patients (approximately 70%) were assigned to a training set, and the remaining 57 patients (approximately 30%) were assigned to a validation set. Predictive model was established using forward stepwise logistic regression and nomogram. Based on factors selected by logistic regression, a one-to-one propensity score matching (PSM) was conducted to compare progression-free survival (PFS) between patients who were present or absent of early TACE refractoriness. PFS curve was estimated by Kaplan-Meier method and compared by log-rank test.Results: Logistic regression revealed that bilobar tumor distribution (p = 0.002), more than three tumors (p = 0.005) and beyond up-to-seven criteria (p = 0.001) were significantly related to early TACE refractoriness. The discriminative abilities, as determined by the area under the receiver operating characteristic (ROC) curve, were 0.788 in the training cohort and 0.706 in the validation cohort. After PSM, the result showed that patients who were absent of early TACE refractoriness had a significantly higher PFS rate than those of patients who were present (p < 0.001).Conclusion: This study presents a predictive model with moderate accuracy to identify patients with high risk of early TACE refractoriness, and patients with early TACE refractoriness may have a poor prognosis.

show abstract

“…[1][2][3] The standard therapy for intermediate-stage HCC is transarterial chemoembolization (TACE), and it has been proven to improve patient survival compared to the best supportive care method. [4][5][6][7][8][9] However, TACE is associated with a high rate of side effects, 10 among which pain is the most common clinical symptom and is frequently associated with prolonged hospitalization and poor compliance for repeat TACE. 11,12 To date, there are various treatment modalities for controlling intra-and post-TACE pain, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids.…”

Section: Introductionmentioning

confidence: 99%

Intraarterial Lidocaine Administration for Pain Control by Water-in-Oil Technique in Transarterial Chemoembolization: in vivo and Randomized Clinical Trial

Wang¹,

Shen

et al. 2021

JHC

View full text Add to dashboard Cite

To investigate the sustained release of lidocaine from a lidocaine-epirubicinlipiodol emulsion created by water-in-oil (W/O) technique in vivo and evaluate the efficacy and safety of intraarterial lidocaine administration for intra-and postoperative pain control in transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Methods: The in vivo concentrations of lidocaine were determined in tumor tissues after VX2 rabbit models for hepatic tumor were administered with intra-arterial lidocaine-epirubicinlipiodol emulsion. A prospective randomized controlled clinical trial was performed, enrolling 70 consecutive patients who underwent TACE. Patients were randomized into two groups: Group A received an immediate bolus intraarterial lidocaine injection before TACE, and Group B received a lidocaine-epirubicin-lipiodol emulsion during TACE. Pain intensity was compared between the two groups using a visual analog scale (VAS) score before (T before ) and at 0 h (T 0 ), 4 h (T 4 ), 8 h (T 8 ), 24 h (T 24 ), 48 h (T 48 ), and 72 h (T 72 ) after the procedure. Adverse events and intake of analgesics were evaluated and compared between the two groups. Results: The concentrations of lidocaine in tumor tissues were higher in experimental group than in control group at T 0.5 (P=0.004), T 1 (P=0.038), T 4 (P=0.036), and T 8 (P=0.029). In the clinical trial, VAS scores in Group B were significantly lower than in Group A at T 0 (P=0.006), T 4 (P=0.001), T 8 (P=0.002), and T 24 (P=0.005). The tramadol intake in Group B was significantly lower than in Group A (P=0.021). No significant difference was observed regarding the incidence of adverse events between the two groups. Conclusion:This study demonstrated the effectiveness and safety of intraarterial lidocaine administration using the W/O technique in controlling intra-and post-TACE pain.

show abstract

Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival

Cited by 9 publications

References 27 publications

Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?

Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?

Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

Intraarterial Lidocaine Administration for Pain Control by Water-in-Oil Technique in Transarterial Chemoembolization: in vivo and Randomized Clinical Trial

Contact Info

Product

Resources

About